US Consumer Health Industry In 2023: Mandatory Listing Has Supplement Sector’s Attention
Executive Summary
Chief executives of OTC drug and supplement industry trade groups discussed potential market and regulatory developments affecting their members’ businesses. HBW Insight reports here on whether support will emerge in Congress for FDA to gain MPL authority for all supplements sold in US.
You may also be interested in...
‘Lack Of Understanding’ Here, Spiked Product There Add Up To US Supplement Industry Image Problem
Research suggesting FDA more stringently regulate claims for fish oil supplements impresses industry as another sign the agency’s regulation and the requirements fulfilled by compliant businesses aren’t appreciated or understood. FDA announcement of ED drugs in products labeled as supplements shows agency must be aware students are starting or returning to classes.
The Dietary Supplement Market US FDA Is Regulating Isn’t Your 1994 DSHEA Version
“In the last 30 years, we've seen this sort of explosion, and it's not just more products and more sales. We're talking about more complex products,” says Cara Welch, FDA Office of Dietary Supplement Programs director. “Today's products are not the products from 1994.”
Absent Mandatory Listing, US FDA Acknowledges Its Supplement Directory Isn’t Comprehensive
Two weeks after Commissioner Califf notes he supports mandatory listing of supplements and two months after previous session of Congress ended without imposing requirement, agency is doing what it can to publish information about ingredients in supplements sold in the country.